Overcoming Drug Resistance in Gynecologic Cancers: Volume 17

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers.

Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

Autorentext
Doctor Riyaz Basha is an Associate Professor & Vice Chair for Research in the Department of Pediatrics and Women's Health, Texas College of Osteopathic Medicine, The University of North Texas Health Science Center (UNTHSC) at Fort Worth, TX, USA. He graduated with a PhD degree in 1999 from the Sri Venkateswara University, Tirupati, India, and received postdoctoral training at the University of Rhode Island, RI, USA. Before joining the UNTHSC in 2013, Dr. Basha was appointed as an Assistant Professor at the Cancer Research Institute of the MD Anderson Cancer Center at Orlando (currently named as UF Cancer Center), Orlando, FL, USA.

Dr. Basha's research is focused on improving cancer therapies in children, adolescents and adults. He has been working closely with physicians and researchers with emphasis on the translational principle of bench to bedside”. He has been investigating on drug resistance and novel strategies to improve the response of standard care/treatment, especially chemotherapy for various cancers including ovarian cancer. He has published his research findings in high impact factor journals such as Journal of Biological Chemistry, Cancer Letters, Cancer Medicine, Critical Reviews in Oncology/Hematology, and Gynecologic Oncology. Dr. Basha is a member of several scientific societies, including the Association of Biotechnology and Pharmacy (ABAP), American Association for Cancer Research, American Society of Clinical Oncology, and American Association for Clinical Chemistry (AACC) Academy. He became Fellow of the ABAP and the AACC Academies, respectively, in 2014 and 2019. He is the recipient of numerous competitive grants from the National Institutes of Health, Hyundai Hope On Wheels, non-profit foundations, and awards including the Young Scientist Travel Award from the Asian Pacific Society for Neurochemistry, four research presentation awards from the Society of Toxicology (USA), and the best presentation award at the International Conference on Drug Discovery and Therapy held in Dubai, UAE. Dr. Basha co-authored more than 100 peer-reviewed publications, served as Guest Editor for two journals, and serving as peer reviewer for more than 50 scientific journals. His research works are extensively cited by the peers globally. Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad's research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

Klappentext
Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers.

Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

Inhalt

1. Introduction to gynecologic cancers: An emphasis on pathogenesis, incidence sand diagnosis

   2. Lifestyle, nutrition, and risk of gynecologic cancers

   3. Drug Resistance in Gynecologic Cancers: Findings and Underlying Mechanisms

   4. Mechanisms of Chemo-resistance and Approaches to Overcome its Impact in Gynecologic Cancers

   5. Drug resistance in gynecologic cancers: Findings and underlying mechanismsCurrent Treatment Modalities in Major Gynecologic Cancers: Emphasis on Response Rates

   6. Drug Resistance in Gynecologic Cancers: Emphasis on Non-coding RNAs and Drug Efflux Mechanisms

   7. Genetic Polymorphisms in Gynecologic Cancers

   8. Overcoming Drug Resistance in Cervical Cancer: Chemo-sensitizing Agents and Targeted Therapies

   9. Immune Response, Inflammation Pathway Gene Polymorphisms and the Risk of Cervical Cancer

   10. Overcoming Chemotherapy Resistance in Endometrial Cancer

   11. Chemoresistance in Uterine Cancer: Mechanisms of Resistance and Current Therapies

   12. Ovarian Cancer: Targeted Therapies and Mechanisms of Resistance

   13. Overcoming Drug Resistance in Ovarian Cancer: Chemo-sensitizing Agents, Targeted Therapies

   14. Resistance to Chemotherapy Among Ethnic and Racial Groups: Health Disparities Perspective in Gynecologic Cancers

   15. Future Perspectives and New Directions in Chemosensitizing Activities to Reverse Drug Resistance in Gynecologic Cancers: Emphasis on Challenges and Opportunities